Manufacturing the vaccines is the responsibility of pharmaceutical companies. In order to ensure that vaccines can be provided quickly to the UK and reduce the risks to its supply of the vaccine, BEIS calculated that it needed to invest £519 million to provide manufacturing capacity for producing the vaccines within the UK. By 8 December 2020, it had committed £302 million to manufacturing projects, including: £127 million to the Cell and Gene Therapy Catapult Manufacturing Centre; £93 million to the Vaccine Manufacturing and innovation Centre; and £42 million to fill and finish facilities. BEIS told us it was confident that, if it needed to, the UK now had sufficient capacity, and a full contingency, to manufacture all the vaccine doses that it might need.37 32 Qq 71–72 33 Q 32 34 Health and Social Care Secretary’s statement on coronavirus (COVID-19), 11 January 2021 35 Qq 5, 22 36 Qq 70–71 37 Qq 45–46, C&AG’s Report, para 18, 2.14–2.15 14 COVID-19: Planning for a vaccine Part 1 2 Part Two – Deploying the vaccines